CDMRP Neurofibromatosis New Investigator Award
ID: 355152Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355152
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Neurofibromatosis New Investigator Award, aimed at supporting innovative research addressing neurofibromatosis (NF). This grant is designed to assist both early-stage and established investigators transitioning into NF research, with a focus on advancing understanding, diagnosis, and treatment of NF types 1, 2, and schwannomatosis, while encouraging diverse research approaches that enhance clinical outcomes. The total funding available for this program is $2.88 million, with an anticipated direct cost limit of $450,000 per project, and applications are due by October 3, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524NFRPNIA_GG.pdf
    The Department of Defense (DOD) has announced the FY24 Neurofibromatosis New Investigator Award under the Defense Health Program, aimed at supporting innovative research that addresses neurofibromatosis (NF). The program provides an opportunity for new and established investigators to pursue research with potentially high impacts relevant to military members and the general public. The total funding available for FY24 is $25 million, with an anticipated direct cost limit of $450,000 for each project. Eligible applicants include researchers affiliated with both extramural and intramural organizations, focusing on advancing understanding, diagnosis, and treatment of NF types 1, 2, and schwannomatosis. The award encourages diverse research approaches, especially those enhancing clinical outcomes, and prohibits clinical trial proposals. The submission process involves a two-step application procedure: submission of a pre-application followed by a full application. Applications will be evaluated based on personnel qualifications, research feasibility, innovation, and potential impact. The peer review process will lead to final funding recommendations, emphasizing the alignment of proposals with the program's strategic goals and areas of emphasis. This program represents significant federal support for ongoing NF research and aims to elevate the quality of care for those affected by the condition while engaging a wide range of research endeavors.
    Similar Opportunities
    Research Program Award (R35 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Research Program Award (R35 Clinical Trial Optional) aimed at providing long-term support and flexibility for Program Directors (PDs) and Principal Investigators (PIs) in the field of neurological research. This grant, which does not require cost sharing or matching, is designed to alleviate the administrative burdens associated with managing multiple grant applications, allowing researchers to focus on their scientific endeavors and mentorship roles. The funding, with an award ceiling of $750,000 and a floor of $350,000, is intended to foster innovative research that aligns with the mission of the National Institute of Neurological Disorders and Stroke (NINDS). Interested applicants can reach out to Alisa Schaefer at nindsr35@ninds.nih.gov for further information, with the estimated synopsis posting date set for April 15, 2026, and a projected award date of March 1, 2027.
    DOD USAMRDC FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRDC), has announced the FY23-FY27 Broad Agency Announcement (BAA) for Extramural Medical Research, which is open for submissions from October 1, 2022, to September 30, 2027. This opportunity invites innovative research proposals that address critical military medical challenges, particularly in the areas of Military Infectious Diseases, Combat Casualty Care, and Military Operational Medicine, with a focus on enhancing medical practices for both military personnel and civilians. The BAA emphasizes the importance of collaboration with Department of Defense and Department of Veterans Affairs resources and requires adherence to strict submission guidelines via Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Interested applicants can submit pre-proposals at any time during the five-year period, with full proposals invited based on initial submissions, and should direct inquiries to the CDMRP Help Desk at help@eBRAP.org.
    Investigate Novel Therapeutic Interventions and Testing Strategies for Neurological Disorders Including to Treat, Modify and Prevent the Development of Epilepsy (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research aimed at investigating novel therapeutic interventions and testing strategies for neurological disorders, specifically targeting the treatment, modification, and prevention of epilepsy. This initiative encourages applicants to explore various intervention modalities and develop human-focused testing approaches, with a particular emphasis on preclinical therapy testing and model development. The total estimated program funding is $6.2 million, with individual awards ranging from $3.5 million to $4 million, and the application process is expected to open with a synopsis posted by December 19, 2025, closing on February 20, 2026. Interested applicants can reach out to Dr. Brian Klein at brian.klein@nih.gov or (301) 496-0981 for further information.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    Notice of Intent to Publish a Funding Opportunity Announcement for Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for research focused on the neurological effects of infection-associated chronic illnesses, including conditions like Neuro-PASC, post-treatment Lyme Disease, and ME/CFS. This initiative aims to promote understanding of the neuropsychiatric manifestations of these illnesses, with a particular interest in projects that explore common mechanisms across multiple conditions, although applications can focus on individual illnesses as well. The anticipated funding amount for this grant is up to $500,000, with the NOFO expected to be published in Fall 2024 and applications due in Winter 2025. Interested applicants should prepare to submit their proposals by the estimated closing date of February 3, 2025, with awards expected to be made by December 1, 2025.
    Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), is offering a Small Research Grant Program (R03) aimed at fostering the next generation of researchers in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This program supports innovative projects that enhance understanding, diagnosis, treatment, and care strategies for AD/ADRD, while also promoting workforce diversity and addressing health disparities in this field. Grants of up to $100,000 for a duration of two years are available, with a total of 12 awards expected for fiscal year 2024, amounting to $1.8 million in funding. Interested applicants must be affiliated with eligible organizations and are encouraged to submit their applications by March 16, 2026, with inquiries directed to grantsinfo@nih.gov for further information.
    Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders" (PAR-25-327), aimed at supporting Investigational New Drug (IND)-enabling studies and preparations for First-in-Human (FIH) clinical trials. This initiative focuses on advancing innovative gene-based therapies, such as oligonucleotides and viral vector approaches, for ultra-rare disorders affecting fewer than 6,000 patients, with an emphasis on projects that demonstrate robust proof of concept data and readiness for clinical trials. Eligible applicants include a wide range of organizations, including higher education institutions and various nonprofit and for-profit entities, with applications requiring detailed project planning and compliance with Good Manufacturing Practices (GMP). The application period opens on January 9, 2025, with a close date of October 8, 2027, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIH Director’s Transformative Research Awards (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce the NIH Director’s Transformative Research Awards, a federal grant opportunity aimed at supporting innovative and unconventional research projects. This program encourages individual scientists or collaborative teams to propose groundbreaking research that has the potential to redefine scientific paradigms or develop transformative technologies, without the need for preliminary data or detailed experimental plans. With an estimated total funding of $8 million and the expectation of awarding seven grants, interested applicants should prepare their proposals in advance, as applications will be solicited starting June 20, 2025, with a closing date of September 3, 2025. For further inquiries, potential applicants can contact Dr. Patricia Labosky at TransformativeAwards@mail.nih.gov or by phone at 301-594-4863.
    INCLUDE Project: Transformative Research Awards for Down syndrome (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the INCLUDE Project: Transformative Research Awards for Down syndrome, aimed at advancing innovative research to improve health and quality of life for individuals with Down syndrome. This funding opportunity invites applications for groundbreaking research that can establish new scientific paradigms or develop transformative technologies related to Down syndrome and its co-occurring conditions, with no preliminary data required. The program has an estimated total funding of $3 million, with individual awards ranging from $250,000 to $500,000, and is expected to support approximately four projects. Interested applicants can reach out to Dr. Charlene Schramm at schrammc@nih.gov or by phone at 301-402-3793, with applications due by February 19, 2026, and anticipated awards announced by September 1, 2026.
    NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS), a federal grant aimed at supporting early-career scientists in advancing their research in mental health. This initiative seeks to foster innovative clinical, translational, or basic research that can significantly enhance the understanding, diagnosis, treatment, or prevention of mental health disorders. With an estimated total program funding of $3 million and the expectation of awarding six grants, this opportunity is designed for small businesses committed to impactful research in the field. Interested applicants can reach out to Dr. Eric R. Murphy at eric.murphy@nih.gov or by phone at 301-443-9230 for further information, with the anticipated synopsis posting date on September 20, 2025, and a closing date of October 20, 2025.